- Home
- ASGI vs SIGA Comparison
ASGI vs SIGA Comparison
Compare ASGI & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASGI
- SIGA
- Stock Information
- Founded
- ASGI 2019
- SIGA 1995
- Country
- ASGI United States
- SIGA United States
- Employees
- ASGI N/A
- SIGA N/A
- Industry
- ASGI Investment Managers
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- ASGI Finance
- SIGA Health Care
- Exchange
- ASGI Nasdaq
- SIGA Nasdaq
- Market Cap
- ASGI 554.6M
- SIGA 515.1M
- IPO Year
- ASGI N/A
- SIGA 1997
- Fundamental
- Price
- ASGI $21.24
- SIGA $6.46
- Analyst Decision
- ASGI
- SIGA
- Analyst Count
- ASGI 0
- SIGA 0
- Target Price
- ASGI N/A
- SIGA N/A
- AVG Volume (30 Days)
- ASGI 83.3K
- SIGA 328.2K
- Earning Date
- ASGI 01-01-0001
- SIGA 08-05-2025
- Dividend Yield
- ASGI 8.76%
- SIGA 9.22%
- EPS Growth
- ASGI N/A
- SIGA N/A
- EPS
- ASGI N/A
- SIGA 0.67
- Revenue
- ASGI N/A
- SIGA $120,330,310.00
- Revenue This Year
- ASGI N/A
- SIGA N/A
- Revenue Next Year
- ASGI N/A
- SIGA $95.31
- P/E Ratio
- ASGI N/A
- SIGA $9.70
- Revenue Growth
- ASGI N/A
- SIGA N/A
- 52 Week Low
- ASGI $14.96
- SIGA $4.95
- 52 Week High
- ASGI $18.55
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- ASGI 64.65
- SIGA 42.33
- Support Level
- ASGI $20.98
- SIGA $6.97
- Resistance Level
- ASGI $21.23
- SIGA $7.32
- Average True Range (ATR)
- ASGI 0.25
- SIGA 0.21
- MACD
- ASGI -0.00
- SIGA -0.07
- Stochastic Oscillator
- ASGI 88.03
- SIGA 7.53
About ASGI abrdn Global Infrastructure Income Fund of Beneficial Interest
abrdn Global Infrastructure Income Fund is a non-diversified, closed-end management investment company. Its objective is to seek to provide a high level of total return with an emphasis on current income by investing in assets that provide necessary services to society.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.